Back to top
more

BioMarin Pharmaceutical (BMRN)

(Delayed Data from NSDQ)

$66.60 USD

66.60
1,644,379

+0.71 (1.08%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $66.63 +0.03 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Can The Uptrend Continue for BioMarin Pharmaceutical?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor BioMarin Pharmaceutical.

BioMarin (BMRN) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

BioMarin (BMRN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

BioMarin's (BMRN) Earnings & Revenues Beat Estimates in Q3

by Zacks Equity Research

BioMarin (BMRN) rides high on earnings and revenue beat in the third quarter of 2019.

HZNP or BMRN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

HZNP vs. BMRN: Which Stock Is the Better Value Option?

BioMarin Pharmaceutical (BMRN) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

BioMarin (BMRN) delivered earnings and revenue surprises of 26.47% and 1.17%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Drug/Biotech Stock Q3 Earnings on Oct 23: LLY, ALXN & More

by Zacks Equity Research

Four drug/biotech stocks are scheduled to release third-quarter results on Oct 23. Let's see how these companies are placed before their earnings call.

BioMarin Pharmaceutical (BMRN) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioMarin (BMRN) Down 7.3% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Sarepta (SRPT) Q2 Loss Widens Y/Y, Golodirsen Nears Approval

by Zacks Equity Research

Sarepta (SRPT) reports wider year-over-year loss. However, revenues increase year over year. The company plans expansion of gene therapy program into other indications including multiple sclerosis.

BioMarin (BMRN) Shares Down on Q1 Earnings & Sales Miss

by Zacks Equity Research

BioMarin (BMRN) announces lower-than-expected earnings and revenues for the second quarter of 2019. It keeps its previously provided revenue guidance intact.

BioMarin Pharmaceutical (BMRN) Lags Q2 Earnings and Revenue Estimates

by Zacks Equity Research

BioMarin (BMRN) delivered earnings and revenue surprises of -47.06% and -5.63%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

What's in the Cards for Sarepta (SRPT) This Earnings Season?

by Zacks Equity Research

Sarepta Therapeutics' (SRPT) Exondys 51 likely to drive second-quarter sales.

BioMarin Pharmaceutical (BMRN) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioMarin (BMRN) to File for Hemophilia A Candidate in Q4

by Zacks Equity Research

BioMarin (BMRN) plans to file regulatory applications for gene therapy candidate for severe hemophilia A in the fourth quarter of 2019.

Sarepta Stock Up Almost 40% This Year So Far: Here's Why

by Zacks Equity Research

Sarepta's (SRPT) key product, Exondys 51, continues to perform well. Its lead pipeline candidate, golodirsen, is nearing approval. The company is also developing gene therapies.

BioMarin Gets $15M From Pfizer on Talzenna's European Nod

by Zacks Equity Research

BioMarin (BMRN) gains a $15-million milestone from Pfizer on the approval of its breast cancer drug in Europe.

Pfizer's Talzenna Gets Approval in Europe for Breast Cancer

by Zacks Equity Research

Pfizer's (PFE) PARP inhibitor, Talzenna, receives approval in Europe for treating BRCA-mutated locally advanced or metastatic breast cancer.

BioMarin's Vimizim Wins Nod in China for Rare Genetic Malady

by Zacks Equity Research

BioMarin's (BMRN) Vimizim gains an NMPA nod in China for addressing patients suffering Morquio A syndrome, an ultra-rare genetic condition.

BioMarin Announces Data on Hemophilia Candidate, Shares Fall

by Zacks Equity Research

BioMarin (BMRN) announces significant reduction in annual bleed rate in phase III study evaluating gene therapy, valoctocogene roxaparvovec, in hemophilia A patients. However, investors are skeptical.

Biotech Stock Roundup: AMGN's Nuevolution Buyout, CELG, INCY Drugs' Label Expansion

by Zacks Equity Research

Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.

BioMarin (BMRN) in Focus: Stock Moves 7.5% Higher

by Zacks Equity Research

BioMarin (BMRN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Sarepta (SRPT) Q1 Earnings Top Estimates, Exondys 51 Sales Up

by Zacks Equity Research

Sarepta (SRPT) beats estimates for both earnings and sales in first-quarter 2019. Exondys 51 continues to perform well on strong demand. Shares up.

BioMarin (BMRN) Shares Down Despite Q1 Earnings & Sales Beat

by Zacks Equity Research

BioMarin's (BMRN) earnings and revenues surpass estimates in the first quarter.

Earnings Preview: BioMarin Pharmaceutical (BMRN) Q1 Earnings Expected to Decline

by Zacks Equity Research

BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

New Strong Sell Stocks for April 16th

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today